Cargando…

Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models

Inhibitors of programmed cell death protein 1 (PD-1) and its ligand (PD-L1) have dramatically changed the treatment landscape for patients with cancer. Clinical activity of anti-PD-(L)1 antibodies has resulted in increased median overall survival and durable responses in patients across selected tum...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kumar, Sujatha, Ghosh, Srimoyee, Sharma, Geeta, Wang, Zebin, Kehry, Marilyn R., Marino, Margaret H., Neben, Tamlyn Y., Lu, Sharon, Luo, Shouqi, Roberts, Simon, Ramaswamy, Sridhar, Danaee, Hadi, Jenkins, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317941/ https://www.ncbi.nlm.nih.gov/pubmed/34313545 http://dx.doi.org/10.1080/19420862.2021.1954136

Ejemplares similares

Dostarlimab: From preclinical investigation to drug approval and future directions
por: Cicala, Carlo Maria, et al.
Publicado: (2023)

Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial
por: Patnaik, Amita, et al.
Publicado: (2021)

Dostarlimab: A Review
por: Costa, Bárbara, et al.
Publicado: (2022)

Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer
por: Alkholifi, Faisal K., et al.
Publicado: (2022)

An Integrated Analysis of Dostarlimab Immunogenicity
por: Lu, Sharon, et al.
Publicado: (2021)

Dostarlimab: A breakthrough in the field of oncology
por: Hussain, Hassan ul, et al.
Publicado: (2022)

Dostarlimab/tozinameran: Various toxicities: case report
Publicado: (2022)

Dostarlimab: The miracle drug for the treatment of colorectal cancer
por: Shuvo, Pollob Ahmed, et al.
Publicado: (2022)

Jemperli (Dostarlimab-gxly): An unprecedented cancer trial
por: Ali, Eman, et al.
Publicado: (2022)

(18)F-FDG PET/CT in Relapsed Endometrial Cancer Treated with Preoperative PD-1 Inhibitor Dostarlimab
por: Seban, Romain-David, et al.
Publicado: (2021)

The High-Resolution Structure Reveals Remarkable Similarity in PD-1 Binding of Cemiplimab and Dostarlimab, the FDA-Approved Antibodies for Cancer Immunotherapy
por: Jeong, Tae-Jun, et al.
Publicado: (2022)

Dostarlimab as a Miracle Drug: Rising Hope against Cancer Treatment
por: Singh, Vanshikha, et al.
Publicado: (2022)

Dostarlimab, a boon or a healthcare burden- too early to acertain!
por: Fatima, Nabeela, et al.
Publicado: (2022)

Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial
por: Oaknin, Ana, et al.
Publicado: (2020)

Immune checkpoint inhibitor-induced encephalitis with dostarlimab in two patients: Case series
por: Marzoughi, Sina, et al.
Publicado: (2021)

Comparative analysis of PD‐1 target engagement of dostarlimab and pembrolizumab in advanced solid tumors using ex vivo IL‐2 stimulation data
por: Austin, Daren, et al.
Publicado: (2022)

IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer
por: Yap, Timothy A, et al.
Publicado: (2022)

An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer
por: Mathews, Cara, et al.
Publicado: (2022)

Correction to: An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer
Publicado: (2022)

The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma
por: Chen, Benjamin J., et al.
Publicado: (2019)

Neuropsychological assessment in preclinical and prodromal Alzheimer disease: a global perspective
por: Watermeyer, Tamlyn, et al.
Publicado: (2019)

A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models
por: Sun, Kaiming, et al.
Publicado: (2018)

An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer
por: Bartoletti, Michele, et al.
Publicado: (2022)

Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer
por: You, Maojin, et al.
Publicado: (2023)

Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
por: Oaknin, Ana, et al.
Publicado: (2023)

Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial
por: André, Thierry, et al.
Publicado: (2023)

Population pharmacokinetics and exposure–response of anti‐programmed cell death protein‐1 monoclonal antibody dostarlimab in advanced solid tumours
por: Melhem, Murad, et al.
Publicado: (2022)

Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma
por: Madariaga, Ainhoa, et al.
Publicado: (2023)

ina-1 expression in the somatic gonad during late larval development
por: Ghosh, Srimoyee, et al.
Publicado: (2016)

Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models
por: Wang, Zebin, et al.
Publicado: (2019)

Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer treated with dostarlimab
por: Kristeleit, Rebecca, et al.
Publicado: (2022)

Promoter-associated DNA methylation & expression profiling of genes (FLT 3, EPB41L3 & SFN) in patients with oral squamous cell carcinoma in the Khasi & Jaintia population of Meghalaya, India
por: Khongsti, Shngainlang, et al.
Publicado: (2019)

A novel trial methodology to test interventions with very large effect sizes: the case of dostarlimab in mismatch repair-deficient, locally advanced rectal cancer
por: Powell, Kerrington, et al.
Publicado: (2022)

Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial
por: Lim, Sun Min, et al.
Publicado: (2023)

Outcomes of dostarlimab versus chemotherapy in post-platinum patients with recurrent/advanced endometrial cancer: data from the GARNET trial and the National Cancer Registration Service in England
por: Goulden, Scott, et al.
Publicado: (2023)

Preclinical to clinical translation of anti-PD-1 blockade
por: Hirsch, Heather, et al.
Publicado: (2015)

Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer
por: BALL, DOUGLAS W., et al.
Publicado: (2015)

Benzothiazinethione is a potent preclinical candidate for the treatment of drug-resistant tuberculosis
por: Gao, Chao, et al.
Publicado: (2016)

Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor
por: Liu, Yahong, et al.
Publicado: (2023)

HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models
por: Ke, Hang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t1vsler6iae1ob22kf66lbhrp2